Ind-Swift Laboratories
Ind-Swift Laboratories Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Ind-Swift Laboratories
Start SIPInd-Swift Laboratories Investment Rating
-
Master Rating:
-
Ind-Swift Labs. (Nse) has an operating revenue of Rs. 1,207.31 Cr. on a trailing 12-month basis. An annual revenue growth of 15% is outstanding, Pre-tax margin of 7% is okay, ROE of 6% is fair but needs improvement. The company has a high debt to equity of 110%, which can be a reason to worry. The stock from a technical standpoint is comfortably placed above its key moving averages, around 11% and 15% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around -2% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 52 which is a POOR score indicating inconsistency in earnings, a RS Rating of 68 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 95 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 290 | 302 | 288 | 272 | 276 |
| Operating Expenses Qtr Cr | 234 | 246 | 231 | 219 | 241 |
| Operating Profit Qtr Cr | 56 | 56 | 57 | 53 | 35 |
| Depreciation Qtr Cr | 9 | 15 | 16 | 16 | 82 |
| Interest Qtr Cr | 22 | 22 | 24 | 24 | 23 |
| Tax Qtr Cr | 39 | -3 | 0 | 0 | 14 |
| Net Profit Qtr Cr | -31 | 29 | 24 | 20 | -63 |
Ind-Swift Laboratories Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹69.9
- 50 Day
- ₹67.17
- 100 Day
- ₹65.44
- 200 Day
- ₹64.54
- 20 Day
- ₹69.4
- 50 Day
- ₹65.4
- 100 Day
- ₹64.83
- 200 Day
- ₹62.85
Ind-Swift Laboratories Resistance and Support
| Resistance | |
|---|---|
| First Resistance | ₹71.6 |
| Second Resistance | ₹72.6 |
| Third Resistance | ₹73.2 |
| RSI | 58.79 |
| MFI | 78.47 |
| MACD Single Line | 1.84 |
| MACD | 1.86 |
| Support | |
|---|---|
| First Resistance | ₹70 |
| Second Resistance | ₹69.41 |
| Third Resistance | ₹68.41 |
Ind-Swift Laboratories Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 166,306 | 10,425,723 | 62.69 |
| Week | 233,880 | 12,776,886 | 54.63 |
| 1 Month | 184,117 | 10,085,924 | 54.78 |
| 6 Month | 97,653 | 5,663,870 | 58 |
Ind-Swift Laboratories Result Highlights
Ind-Swift Laboratories Synopsis
NSE-Medical-Generic Drugs
Ind-Swift Laboratori is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1151.96 Cr. and Equity Capital is Rs. 59.81 Cr. for the Year ended 31/03/2023. Ind-Swift Laboratories Ltd. is a Public Limited Listed company incorporated on 04/01/1995 and has its registered office in the State of Chandigarh, India. Company’s Corporate Identification Number(CIN) is L24232CH1995PLC015553 and registration number is 015553.| Market Cap | 430 |
| Sales | 1,152 |
| Shares in Float | 3.43 |
| No of funds | 3 |
| Yield |
| Book Value | 0.65 |
| U/D Vol ratio | 1.6 |
| LTDebt / Equity | 110 |
| Alpha | 0.05 |
| Beta | 0.69 |
Ind-Swift Laboratories
| Owner Name | Mar-23 | Dec-22 | Sep-22 | Jun-22 |
|---|---|---|---|---|
| Promoters | 42% | 42% | 42% | 42% |
| Foreign Portfolio Investors | 0.04% | |||
| Individual Investors | 29.08% | 28.97% | 29.06% | 29.55% |
| Others | 28.92% | 28.99% | 28.94% | 28.45% |
Ind-Swift Laboratories Management
| Name | Designation |
|---|---|
| Mr. N R Munjal | Chairman & Managing Director |
| Mr. Himanshu Jain | Joint Managing Director |
| Mr. Rishav Mehta | Executive Director |
| Mr. Sahil Munjal | Executive Director |
| Dr. Ashwani Kumar Vig | Independent Director |
| Mr. Rajinder Kumar Gupta | Independent Director |
| Mr. S P Sharma | Independent Director |
| Ms. Neerja Chathley | Independent Woman Director |
Ind-Swift Laboratories Forecast
Price Estimates
Ind-Swift Laboratories Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2023-05-29 | Audited Results | |
| 2023-02-14 | Quarterly Results | |
| 2022-11-08 | Quarterly Results | |
| 2022-08-10 | Quarterly Results | |
| 2022-05-28 | Audited Results |
Ind-Swift Laboratories FAQs
What is Share Price of Ind-Swift Laboratories ?
Ind-Swift Laboratories share price is ₹72 As on 06 June, 2023 | 08:13
What is the Market Cap of Ind-Swift Laboratories ?
The Market Cap of Ind-Swift Laboratories is ₹430.7 Cr As on 06 June, 2023 | 08:13
What is the P/E ratio of Ind-Swift Laboratories ?
The P/E ratio of Ind-Swift Laboratories is 8.9 As on 06 June, 2023 | 08:13
What is the PB ratio of Ind-Swift Laboratories ?
The PB ratio of Ind-Swift Laboratories is 0.6 As on 06 June, 2023 | 08:13